- 1 Interaction-based feature selection algorithm outperforms
- 2 polygenic risk score in predicting Parkinson's Disease
- 3 status

7

- 5 Jörn E. Klinger¹, Charles N. J. Ravarani¹, Hannes A. Baukmann¹, Justin L. Cope¹,
- 6 Erwin P. Böttinger², Stefan Konigorski², Marco F. Schmidt^{1*}
- 8 ¹biotx.ai GmbH, Am Mühlenberg 11, 14476 Potsdam, Germany
- 9 ²Digital Health Center, Hasso Plattner Institute for Digital Engineering, University of
- 10 Potsdam, Rudolf-Breitscheid-Straße 187, 14482 Potsdam, Germany
- 12 *Corresponding author
- 13 E-mail: ms@biotx.ai

Abstract

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

Polygenic risk scores (PRS) aggregating results from genome-wide association studies are state of the art to predict the susceptibility to complex traits or diseases. Novel machine learning algorithms that use large amounts of data promise to find gene-gene interactions in order to build models with better predictive performance than PRS. Here, we present a data preprocessing step by using data-mining of contextual information to reduce the number of features, enabling machine learning algorithms to identify gene-gene interactions. We applied our approach to the Parkinson's Progression Markers Initiative (PPMI) dataset, an observational clinical study of 471 genotyped subjects (368 cases and 152 controls). With an AUC of 0.85 (95% CI = [0.72; 0.96]), the interaction-based prediction model outperforms the PRS (AUC of 0.58) (95% CI = [0.42; 0.81])). Furthermore, feature importance analysis of the model provided insights into the mechanism of Parkinson's Disease. For instance, the model revealed an interaction of previously described drug target candidate genes TMEM175 and GAPDHP25. These results demonstrate that interaction-based machine learning models can improve genetic prediction models and might provide an answer to the missing heritability problem.

Introduction

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

The need to understand how to predict phenotypes from genetic data becomes evermore important for individual's disease risk prediction, animal and plant breeding as well as genome editing. Polygenic risk scores (PRS), simple additive models, are state of the art to investigate the genetic architecture and, more importantly, to predict the susceptibility of complex traits or diseases. (Wray et al., 2007; Evans et al., 2009; International Schizophrenia Consortium et al., 2009) For each individual a score is calculated as a weighted sum of the number of risk allele single nucleotide polymorphisms (SNP) an individual was tested for. The used weights are regression coefficients from previous genome-wide association studies (GWAS). Importantly, PRS models are not optimized for predictive performance. (Chatteriee et al., 2013; Dudbridge, 2013) There are three reasons for this: 1. Due to the current limited sample size of discovery GWAS datasets (< 1,000,000 individuals), biologically relevant rare variants with small effect sizes cannot be detected. Additionally, the limited sample sizes of discovery GWAS can lead to biased PRS models that might not perform well in populations with ancestry different to that of the discovery dataset. (Reisberg et al., 2017; Duncan et al., 2019) 2. It has been shown that statistically associated SNPs are not automatically good predictors. (Lo et al., 2015) 3. It has been reported that genetic effects discovered in genome-wide association studies do not sum to the estimate of the heritability of the trait compared to twin studies. (Yang et al., 2010) This has been called the missing heritability problem in GWAS. (Manolio et al., 2009) Beside potentially missing relevant rare variants and suboptimal SNP selection based on p values, classical PRS models ignore complex gene-gene interactions, also known as epistasis, of the trait or disease due to their simple additive structure.

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

The concept of epistasis has been described more than 100 years ago. (Bateson and William, 1906) Statistical epistasis, as observed in genome-wide association studies, is genetic variance that can be attributed to gene interaction and is defined as a function of the allele frequencies in a population. Detection of epistasis in discovery GWAS and modeling its impact is challenging because of linkage disequilibrium (LD), replication of identified gene-gene interactions in validation datasets, model complexity, and high dimensionality. (Wei et al., 2014) Machine learning algorithms that improve automatically through experience and by the use of data represent an opportunity to find gene-gene interactions in order to build prediction models with better predictive performance than PRS. Nevertheless, in a recent study a PRS model outperformed the five machine learning algorithms Naïve Bayes classifier, regularized regression, random forest, gradient boost, and support vector machine used to build prediction models for coronary artery diseases status. (Gola et al., 2020) Here, we explore the potential of using contextual information obtained via data mining to strongly reduce the hypothesis space, which, in turn, allows for testing a small set of complex hypotheses, containing interaction of multiple variants. This approach organizes data mined from journal articles, pathway libraries, protein co-expression libraries and drug candidate libraries into a hierarchical graph, which generates disease-specific hypotheses based on interactions of genetic variants. Each interaction's predictive power is determined using the training data set. If an interaction predicts disease status well, the graph is incentivized to 'fine-tune' the hypothesis by comparing a set of very similar hypotheses. If a hypothesis has little or no predictive power, the graph is not incentivized to explore it, or similar hypotheses further and will instead propose hypotheses containing different variants. This learning process is driven by gradient descent, meaning that it converges when the average performance of the new multi-variant hypothesis does not increase. After convergence, the selected features are used to build prediction models with standard machine learning algorithms, such as LASSO (least absolute shrinkage and selection operator) regression (Friedman et al., 2010). An overview of our approach is given in Figure 1. The Parkinson's Progression Markers Initiative (PPMI) dataset (Marek et al., 2011, 2018) (https://www.ppmi-info.org) was selected for the comparison as the dataset has been intensively analyzed and, from there, a broad audience is able to reproduce our results.

Results

GWAS

In a preliminary proof-of-concept step, a genome-wide association (GWA) analysis was performed. For all 471 subjects in the PPMI database, 368 cases and 152 controls, subject genotyping information was collected from two complementary genotyping chips (NeuroX and ImmunoChip). After careful quality control and harmonization, we merged that information into a single dataset with 369,036 variants and 436 individuals. The Manhattan plot of the p values resulting from SAIGE analysis is shown in Fig. 2. Seven single nucleotide polymorphisms (SNPs) showed smaller p values than 10^{-4} (Table 1).

Polygenic risk score

For all analyses described in the following, the data was split into training, validation and test sets. The same sets were used for constructing a polygenic risk score (PRS) and machine learning prediction models with and without feature selection. To calculate the PRS, 7 different p value thresholds (0.001, 0.05, 0.1, 0.2, 0.4, 0.5) for the

subjects in the training, validation and test set were used. The PRS of the subjects in the training set were then used to train a separate logistic regression classifier for each p value threshold. The validation data set was used to determine which of these thresholds produces the best classifier, which was then used to predict the test set. This classifier is based on the PRS of 57 different SNPs.

The receiver operating characteristics (ROC) curve was used to evaluate the predictive power of the PRS. The area under the curve (AUC) was 0.58 (95% CI = [0.42; 0.81]) and the Youden's index was 0.21 (Tab. 2).

Deep learning

Deep learning is a machine learning technique based on artificial neural networks with representation learning that allows a system to automatically discover the representations needed for feature detection or classification from raw data. Despite not being widely used in the field of genomics, there is work on applying Deep Learning to GWAS, such as Romero *et al.* (Romero *et al.*, 2016). Romero *et al.* use a Diet Network, a neural network parameterization, which considerably reduces the number of free parameters. The model is composed of 3 networks, one basic and two auxiliary networks. After a basic discriminative network with optional reconstruction path, a network that predicts the input fat layer parameters, and finally, a network that predicts the reconstruction fat layer parameters. We applied their approach to the PPMI dataset. The area under the curve (AUC) of the deep learning model was 0.67 (95% CI = [0.47; 0.83]) and the Youden index was 0.29 (Tab. 2). Notably, the deep learning model contains abstract embeddings instead of concrete SNPs as in the PRS.

Feature selection and LASSO regression

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

The hierarchical graph, as well as the training set of the GWAS data were used to select a set of less than 100 polygenic hypotheses using our approach as described in the introduction above. The remaining hypotheses were summarized in a term that was used to train a LASSO regression model on the validation data. (Tibshirani, 1996) This model, based on 47 SNPs in several different interaction terms, then predicted the test set. The area under the curve (AUC) for the LASSO model with prior feature selection was 0.85 (95% CI = [0.72; 0.96]) and the Youden index was 0.61. A LASSO model without prior feature selection that was built for comparison did not deliver outcomes that were significantly better than chance (Tab. 2). Exploring the feature selection based model with its interactive terms, provides insights about the genes associated with the disease. An annotation of all 47 SNPs in our model can be found in the Supplementary Information. An exciting result from this analysis of the PPMI dataset is the statistical interaction of variants rs3822019 on chromosome 4 in gene TMEM175, coding for a potassium channel in late endosomes, and rs17022452 on chromosome 2, close to the coding region of GAPDHP25, glyceraldehyde-3 phosphate dehydrogenase pseudogene 25. rs3822019 is an intron variant that has been linked to Parkinson's Disease. (Nalls et al., 2014)

Discussion

We analyzed the PPMI dataset and built predictive models using PLINK for a polygenic risk score, a diet-net deep learning algorithm for genomic data (Romero et al., 2016), and LASSO regression with and without the above proposed approach of using contextual data to reduce the hypothesis space. The PRS model comprises 16,135 SNPs and showed an AUC of 0.56 whereas the deep learning model had an AUC of

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

0.52. Notably, the deep learning model consists of abstract embeddings instead of single SNPs like the PRS. Therefore, identification of disease-associated SNPs and further insights into the disease mechanism are not possible here. The LASSO regression model built on interactions containing only 47 SNPs that were discovered via the use of contextual information outperformed the other predictive models with an AUC of 0.82. Beyond that, the approach was able to associate new variants with the disease that would have not shown up under an additive approach such as PRS. We investigated how the combinations of the relevant genotypes rs3822019 TT (TMEM175) and rs17022452 GG (GAPDHP25) split the individuals into cases and controls (Tab. 3). All subjects that are homozygous for rs3822019 TT are affected by PD. Furthermore, most individuals heterozygous for this variant (rs3822019 TT) or homozygous for rs17022452 GG are cases (76.4% and 75.0%, respectively). These results support the relevance of the association between these variants and PD status. The TMEM175/GAK/DGKQ locus was the third strongest risk locus in a GWA study of Parkinson's disease (Krohn et al., 2020) and has been described as a potential drug target. (Diogo et al., 2018; Jinn et al., 2019) Deficiency in the potassium channel TMEM175 results in unstable lysosomal pH, which leads to decreased lysosomal catalytic activity and increased α-synuclein aggregation, among other effects. As a potassium channel, TMEM175 has a high potential as a druggable target anda tractable therapeutic strategy has been proposed. (Jinn et al., 2017) GAPDH has been targeted with the investigational drug Omigapil for prevention of PD. ALS, congenital muscular dystrophy and myopathy. The drug has been shown to protect against behavioural abnormalities and neuro-degeneration in animal models of Parkinson's disease. However, PD development has been terminated due to lack of benefit. (Olanow et al., 2006)

There seem to be various causes of Parkinson's Disease, yet the pathogenesis of this disease appears to be converging on common themes—oxidative stress, mitochondrial dysfunction, and protein aggregation—all of which are tightly linked to autophagy. (Lynch-Day et al., 2012) Both TMEM175 (Jinn et al., 2019) and GAPDH(Butera et al., 2019) regulate autophagy. Disturbed expression of autophagy genes in blood of PD patients. (Lynch-Day et al., 2012) To summarize, we here present an approach to apply machine learning algorithms to high-dimensional genomic data using a contextual knowledge based feature selection. PRS models require a large set of SNPs, which leads to overfitting and limits their use in clinical practice. We generated more parsimonious models overcoming these limitations – with only 47, partly interacting SNPs, our model was able to outperform a PRS model based on 57 SNPs for Parkinson's Disease. Analysis of feature importance of our model identified a gene-gene interaction of TMEM175 and GAPDHP25. TMEM175 has been described as a potential drug target and further information on its mechanism of action could be invaluable. A recently discovered interaction with pseudogene GAPDHP25 could provide helpful insights. In conclusion, applying machine learning algorithms to feature-selected genomic data leads to interactionbased models with better predictive performance than PRS as well as paves the way to generate new insights into disease mechanisms.

Methods

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

Parkinson's progression marker initiative dataset

The Parkinson's progression marker initiative (PPMI) dataset (https://www.ppmi-info.org) contains 471 subjects, 368 cases and 152 controls, for each subject genotyping information from two complementary chips (NeuroX and ImmunoChip) was

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

collected. (Marek et al., 2011) After careful quality control and harmonization (e.g. genome build, strand alignment) as described in the literature (Marees et al., 2018) we merged that information into a single dataset with 380,939 variants in total. An additional set of quality control steps were performed on variants and individuals that aimed to remove biases that could affect the downstream analysis. In more detail, in a first stage SNPs and individuals were filtered based on their missingness in the dataset. This ensures that SNPs are excluded that have a high proportion of subjects where genotyping information was unavailable or of poor quality. Similarly, individuals where a large proportion of SNPs could not be measured were excluded. This step was achieved by setting a threshold of 0.02 (i.e. >2%; 6,084 variants and 22 people were removed). SNP filtering was performed before individuals were filtered. With high missing rates filtered, all variants not on autosomal chromosomes were removed (5,731 variants were removed). This was followed by the identification and removal of variants that deviate from the Hardy-Weinberg equilibrium. These variants were identified in a two-stage process whereby we first applied a threshold of 1e-6 exclusively to controls, followed by a threshold of 1e-10 applied to all samples (0 and 202 variants were removed). This is a common indicator of genotyping errors. Next, individuals were filtered based on their heterozygosity rates which can indicate sample contamination. Individuals that deviate by more than 3 standard deviations from the mean of the rate from all samples (13 individuals were removed) were filtered out. To assess the heterozygosity rate per sample, the variants that were in linkage disequilibrium with each other were first extracted, scanning the genome at a window size of 50 variants, step size of 5 and a pairwise correlation threshold of 0.2.

Finally, related individuals were removed, which was achieved through the assessment of their respective identity by descent coefficients (IBD) that were calculated. Only one individual in a related pair would be kept (0 individuals were removed).

The final quality-controlled dataset contained 369,036 variants and 436 individuals passing the various filters.

GWAS

In a preliminary proof-of-concept step, a genome-wide association (GWA) analysis was performed with the R package SAIGE (Zhou et al., 2018) to test individual variants for their association with Parkinson's Disease.

Polygenic risk score

The data (n = 436) was then split into training (n = 367), validation (n = 33) and test sets (n = 36). The same sets were used for constructing a polygenic risk score (PRS) and machine learning prediction models with and without feature selection. To calculate the PRS, different p value thresholds for the subjects in the training, validation and test set were used. The PRS was constructed by using PLINK(Purcell et al., 2007) following the guidelines provided by Choi et al. (Choi et al., 2020) and the accompanying tutorial (https://choishingwan.github.io/PRS-Tutorial/plink/.) The clumping cut-off of r^2 was 0.1. The p-value threshold was 0.05 for the subjects in the training, validation, and test sets. The PRS of the subjects in the training set were then used to train a separate logistic regression classifier using the glm function in R (www.R-project.org) for each p value threshold. The validation data set was used to determine which of these thresholds produces the best classifier, which was then used to predict the test set.

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Deep learning The deep learning prediction model was built using a Diet Network according to the procedure described by Romero et al., (Romero et al., 2016) The official code can be found here: https://github.com/adri-romsor/DietNetworks. **Feature selection** A knowledge graph containing contextual information mined from public databases such as e.g. dbSNP, ClinVar, OMIM, Reactome, STRING database proposes 100 SNPs and SNP-SNP interactions. The proposed SNPs and SNP-SNP interactions are evaluated in the training data by drop one model comparison procedure using the glm function in R (www.R-project.org). (Klinger et al.) A gradient descent algorithm directs the search across the graph based on whether proposed hypotheses are correlated with the disease status or not and corrects accordingly the SNP and SNP-SNP interactions list until all members of the list show strong correlation with the disease status. LASSO regression LASSO regression models were computed by using the glmnet package (https://glmnet.stanford.edu/index.html for R (www.R-project.org) and its function cv.glmnet. (Friedman et al., 2010) **Acknowledgements** Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-todate information on the study, visit www.ppmi-info.org. PPMI - a public-private

partnership – is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners. List the full names of all of the PPMI funding partners can be found at www.ppmi-info.org/fundingpartners. The research work was supported by the Investitionsbank des Landes Brandenburg (ILB), the European Regional Development Fund (ERDF), and the European Social Fund+ (ESF+). We also thank the program digital solutions made in Brandenburg (digisolBB) for its continued support.

References

296

318

297 Bateson, and William (1906). The progress of genetics since the rediscovery of 298 Mendel's papers. Progress. Rei Bot. 1, 368. 299 Butera, G., Mullappilly, N., Masetto, F., Palmieri, M., Scupoli, M. T., Pacchiana, R., et 300 al. (2019). Regulation of Autophagy by Nuclear GAPDH and Its Aggregates in 301 Cancer and Neurodegenerative Disorders. Int. J. Mol. Sci. 20. 302 doi:10.3390/ijms20092062. Chatterjee, N., Wheeler, B., Sampson, J., Hartge, P., Chanock, S. J., and Park, J.-H. 303 304 (2013). Projecting the performance of risk prediction based on polygenic analyses 305 of genome-wide association studies. *Nat. Genet.* 45, 400–5, 405e1–3. 306 Choi, S. W., Mak, T. S.-H., and O'Reilly, P. F. (2020). Tutorial: a guide to performing 307 polygenic risk score analyses. Nat. Protoc. 15, 2759–2772. 308 Diogo, D., Tian, C., Franklin, C. S., Alanne-Kinnunen, M., March, M., Spencer, C. C. 309 A., et al. (2018). Phenome-wide association studies across large population 310 cohorts support drug target validation. Nat. Commun. 9, 4285. 311 Dudbridge, F. (2013). Power and predictive accuracy of polygenic risk scores. PLoS 312 Genet. 9, e1003348. 313 Duncan, L., Shen, H., Gelaye, B., Meijsen, J., Ressler, K., Feldman, M., et al. (2019). 314 Analysis of polygenic risk score usage and performance in diverse human 315 populations. Nat. Commun. 10, 3328. 316 Evans, D. M., Visscher, P. M., and Wray, N. R. (2009). Harnessing the information 317 contained within genome-wide association studies to improve individual prediction

of complex disease risk. Hum. Mol. Genet. 18, 3525–3531.

319 Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization Paths for 320 Generalized Linear Models via Coordinate Descent. J. Stat. Softw. 33, 1–22. 321 Gola, D., Erdmann, J., Müller-Myhsok, B., Schunkert, H., and König, I. R. (2020). 322 Polygenic risk scores outperform machine learning methods in predicting coronary 323 artery disease status. Genet. Epidemiol. 44, 125-138. 324 International Schizophrenia Consortium, Purcell, S. M., Wray, N. R., Stone, J. L., 325 Visscher, P. M., O'Donovan, M. C., et al. (2009). Common polygenic variation 326 contributes to risk of schizophrenia and bipolar disorder. *Nature* 460, 748–752. 327 Jinn, S., Blauwendraat, C., Toolan, D., Gretzula, C. A., Drolet, R. E., Smith, S., et al. 328 (2019). Functionalization of the TMEM175 p.M393T variant as a risk factor for 329 Parkinson disease. Hum. Mol. Genet. 28, 3244–3254. 330 Jinn, S., Drolet, R. E., Cramer, P. E., Wong, A. H.-K., Toolan, D. M., Gretzula, C. A., 331 et al. (2017). TMEM175 deficiency impairs lysosomal and mitochondrial function 332 and increases α-synuclein aggregation. Proc. Natl. Acad. Sci. U. S. A. 114, 2389-333 2394. 334 Klinger, J., Ravarani, C., Bannard, C., Lamparter, M., Schwinges, A., Cope, J., et al. 335 Critically ill COVID-19 status associated trait genetics reveals CDK6 inhibitors as 336 potential treatment. doi:10.21203/rs.3.rs-568366/v1. 337 Krohn, L., Öztürk, T. N., Vanderperre, B., Ouled Amar Bencheikh, B., Ruskey, J. A., 338 Laurent, S. B., et al. (2020). Genetic, Structural, and Functional Evidence Link 339 TMEM175 to Synucleinopathies. Ann. Neurol. 87, 139–153. 340 Lo, A., Chernoff, H., Zheng, T., and Lo, S.-H. (2015). Why significant variables aren't 341 automatically good predictors. Proc. Natl. Acad. Sci. U. S. A. 112, 13892–13897.

342 Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., and Klionsky, D. J. (2012). The role of 343 autophagy in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2, a009357. 344 Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., 345 et al. (2009). Finding the missing heritability of complex diseases. Nature 461, 346 747–753. 347 Marees, A. T., de Kluiver, H., Stringer, S., Vorspan, F., Curis, E., Marie-Claire, C., et 348 al. (2018). A tutorial on conducting genome-wide association studies: Quality 349 control and statistical analysis. Int. J. Methods Psychiatr. Res. 27, e1608. 350 Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell-Garcia, C., 351 et al. (2018). The Parkinson's progression markers initiative (PPMI) - establishing 352 a PD biomarker cohort. Ann Clin Transl Neurol 5, 1460–1477. 353 Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., et al. (2011). 354 The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629-355 635. 356 Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., et al. 357 (2014). Large-scale meta-analysis of genome-wide association data identifies six 358 new risk loci for Parkinson's disease. Nat. Genet. 46, 989–993. 359 Olanow, C. W., Schapira, A. H. V., LeWitt, P. A., Kieburtz, K., Sauer, D., Olivieri, G., et 360 al. (2006). TCH346 as a neuroprotective drug in Parkinson's disease: a double-361 blind, randomised, controlled trial. *Lancet Neurol.* 5, 1013–1020. 362 Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., et 363 al. (2007). PLINK: a tool set for whole-genome association and population-based 364 linkage analyses. Am. J. Hum. Genet. 81, 559-575.

Reisberg, S., Iliasenko, T., Läll, K., Fischer, K., and Vilo, J. (2017). Comparing 365 366 distributions of polygenic risk scores of type 2 diabetes and coronary heart disease within different populations. PLoS One 12, e0179238. 367 368 Romero, A., Carrier, P. L., Erragabi, A., Sylvain, T., Auvolat, A., Dejoie, E., et al. (2016). 369 Diet Networks: Thin Parameters for Fat Genomics. arXiv [cs.LG]. Available at: 370 http://arxiv.org/abs/1611.09340. 371 Tibshirani, R. (1996). Regression shrinkage and selection via the lasso. J. R. Stat. Soc. 372 58, 267–288. 373 Wei, W.-H., Hemani, G., and Haley, C. S. (2014). Detecting epistasis in human 374 complex traits. Nat. Rev. Genet. 15, 722-733. Wrav. N. R., Goddard, M. E., and Visscher, P. M. (2007). Prediction of individual 375 376 genetic risk to disease from genome-wide association studies. Genome Res. 17, 377 1520-1528. 378 Yang, J., Benyamin, B., McEvoy, B. P., Gordon, S., Henders, A. K., Nyholt, D. R., et 379 al. (2010). Common SNPs explain a large proportion of the heritability for human 380 height. Nat. Genet. 42, 565-569. 381 Zhou, W., Nielsen, J. B., Fritsche, L. G., Dev, R., Gabrielsen, M. E., Wolford, B. N., et 382 al. (2018). Efficiently controlling for case-control imbalance and sample 383 relatedness in large-scale genetic association studies. Nat. Genet. 50, 1335–1341.

Figures and Tables

Figure 1




Fig. 1. Our feature selection consists of two complementary modules that are in feedback with each other. The contextual module uses information mined from the scientific literature, pathway libraries and protein co-expression data and an evaluation module that estimates predictive power of a feature based on that contextual information. The selected features can be used to build prediction models with standard machine learning algorithms.

Figure 2




Fig. 2. Manhattan plot of negative decadic logarithm of p values for SNPs as determined by SAIGE analysis. Variants identified by our biotx ai model are highlighted in red and green if they increase or decrease disease risk, respectively. Variants highlighted in orange occur in both protective and risk-enhancing groups of SNPs, depending on their genotype. Most of these biologically meaningful variants would have been missed by using a simple p value cutoff.

Figure 3




Fig. 3. Receiver operating characteristic (ROC) curves of feature selected machine learning model (left) and polygenic risk score (right). The AUC of the feature selected model with 0.85 (95% CI = [0.72; 0.96]) is better than the AUC of the PRS with 0.56 (95% CI = [0.42; 0.81]).

412 Figure 4




Fig. 4. Coefficients determined by our biotx.ai model for SNPs and groups of SNPs. Negative values (green) indicate protective (combinations of) variants, positive values (red) mark risk variants. The respective genotypes of each variant are indicated by one-letter codes of the bases, where the first letter corresponds to the reference allele, and the second corresponds to the observed, alternative allele.

Table 1

Tab 1. PPMI GWAS results identified 7 SNPs with a p value < 10⁻⁴. Positions and rs

IDs according to Human Genome Reference hg19 (GRCh37).

Ch r	Pos	SNP ID	rs ID	Genic Context	p value
1	173266578	imm_1_17 1533201	rs4916319	TNFSF4 (upstream)	0.000083
2	209087335	exm22611 59	rs4675743		0.000046
5	156376703	exm49891 7	rs6873053	TIMD4 (downstream)	0.000092
6	133716974	rs212805	rs212805	EYA4	0.000074
17	25895033	imm_17_2 2919160	rs4795747		0.000015
18	5479093	rs7238186	rs7238186	EPB41L3 (downstream)	0.000007
19	57909872	exm15132 84	rs4801478	ZNF548	0.000040

Table 2

Tab. 2. Performance comparison of all models.

Method	AUC [95% CI]	Accuracy	Sensitivity	Specificity	Youden's Index
PRS	0.56 [0.42; 0.81]	0.60	0.62	0.56	0.21
Deep learning	0.67 [0.47; 0.83]	0.60	0.42	0.88	0.29
LASSO w/ feature selection	0.85 [0.72; 0.96]	0.81	0.81	0.80	0.61
LASSO w/o feature selection	0.51 [0.39; 0.63]	0.62	0.87	0.09	0.12

Table 3

473

474

475

476

477

Tab. 3. PD cases and controls among bearers of the respective genotype combinations

of the identified variants rs3822019 and rs17022452.

Genotype combination	cases	controls
rs3822019_TT / rs17022452_GG	0	0
rs3822019_TT / rs17022452_GA	6 / 100%	0
rs3822019_TC / rs17022452_GG	2 / 50%	2 / 50%
rs3822019_TT / -	7 / 100%	0
- / rs17022452_GG	7 / 87.5%	1 / 12.5%
rs3822019_TC / rs17022452_GA	27 / 87.1%	4 / 12.9%
rs3822019_TC / -	68 / 73.9%	24 / 26.1%
- / rs17022452_GA	66 / 75%	22 / 25%
-/-	113 / 56.5%	87 / 43.5%